Lunai Bioworks (LNAI) Change in Receivables (2014 - 2026)
Lunai Bioworks (LNAI) posted quarterly Change in Receivables of $62079.0 for Q1 2026, up 2867.45% year-over-year from $2092.0 in Q1 2025, and up 3447.37% quarter-over-quarter from $1750.0 in Q4 2025.
Lunai Bioworks (LNAI) Change in Receivables (2014 - 2026) Analysis & Trends
Lunai Bioworks' Change in Receivables history runs 12 years deep, the most recent figure standing at $62079.0 for Q1 2026.
- In Q1 2026, Change in Receivables rose 2867.45% year-over-year to $62079.0; the TTM figure through Mar 2026 stood at -$96662.0 (down 179.64% YoY), while the FY2025 annual figure was -$1.2 million, down 204.11% from the prior year.
- Change in Receivables for Q1 2026 stood at $62079.0, up from $1750.0 in the prior quarter.
- The five-year high for Change in Receivables was $1.1 million in Q2 2024, with the low at -$1.2 million in Q4 2024.
- The 4-year median for Change in Receivables is $2092.0 (2025), against an average of $2246.8.
- The sharpest annual moves came in 2025 and 2026: Change in Receivables plunged 115.06% in 2025, then soared 2867.45% in 2026.
- Lunai Bioworks' Change in Receivables stood at -$4034.0 in 2022, then sank by 29273.4% to -$1.2 million in 2024, then soared by 100.15% to $1750.0 in 2025, then soared by 3447.37% to $62079.0 in 2026.
- Business Quant data shows LNAI's Change in Receivables at $62079.0 in Q1 2026, $1750.0 in Q4 2025, and $6407.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lunai Bioworks | 6.87 Mn | 3.72 Mn | 20,942.00 | 62,079.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 62,079.00 |
| Mar 31, 2026 | 62,079.00 |
| Dec 31, 2025 | 1,750.00 |
| Dec 31, 2025 | 1,750.00 |
| Sep 30, 2025 | 6,407.00 |
| Sep 30, 2025 | 6,407.00 |
| Jun 30, 2025 | -166,898.00 |
| Jun 30, 2025 | -166,898.00 |
| Mar 31, 2025 | 2,092.00 |
| Mar 31, 2025 | 2,092.00 |
| Dec 31, 2024 | -1.18 Mn |
| Dec 31, 2024 | -1.18 Mn |
| Sep 30, 2024 | 195,961.00 |
| Sep 30, 2024 | 195,961.00 |
| Jun 30, 2024 | 1.11 Mn |
| Jun 30, 2024 | 1.11 Mn |
| Dec 31, 2022 | -4,034.00 |
| Dec 31, 2022 | -4,034.00 |
| Sep 30, 2022 | 3,988.00 |
| Sep 30, 2022 | 3,988.00 |